Advances in the management of pulmonary arterial hypertension

Himanshu Deshwal, Tatiana Weinstein, Roxana Sulica

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


The management of pulmonary arterial hypertension (PAH) has significantly evolved over the last decades in the wake of more sensitive diagnostics and specialized clinical programs that can provide focused medical care. In the current era of PAH care, 1-year survival rates have increased to 86%-90% from 65% in the 1980s, and average long-term survival has increased to 6 years from 2.8 years. The heterogeneity in the etiology and disease course has opened doors to focusing research in phenotyping the disease and understanding the pathophysiology at a cellular and genetic level. This may eventually lead to precision medicine and the development of medications that may prevent or reverse pulmonary vascular remodeling. With more insight, clinical trial designs and primary end-points may change to identify the true survival benefit of pharmacotherapy. Identifying responders from non-responders to therapy may help provide individualized patient-centered care rather than an algorithm-based approach. The purpose of this review is to highlight the latest advances in screening, diagnosis, and management of PAH.

Original languageEnglish
Pages (from-to)1270-1280
Number of pages11
JournalJournal of Investigative Medicine
Issue number7
StatePublished - 1 Oct 2021
Externally publishedYes


  • cardiology
  • heart failure
  • hypertension
  • lung transplantation
  • pulmonary
  • respiration disorders


Dive into the research topics of 'Advances in the management of pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this